

28 June 2024

Our Ref: RFI 56256**Freedom of Information Act 2000
Information in Relation to Dermatology and Respiratory Medicine.**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 1 February 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery, Elective Care, Maternity & Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Caroline Degans
Information Governance Officer

Q1. How many patients were treated in January 2024 (or latest available month) by the Dermatology Department with the following drugs:

A1. Please see Table 1 for the number of patients treated by the Dermatology Department with the listed drugs for the month of October 2023*.

Table 1

Drug Type	Number of Patients Treated
Abrocitinib (Cibinqo)	Nil
Baricitinib (Olumiant)	Nil
Dupilumab (Dupixent)	57
Lebrikizumab (Ebglyss)	Nil
Omalizumab (Xolair)	2
Tralokinumab (Adtralza)	Nil
Upadacitinib (Rinvoq)	4

Q2. Now many patients were treated in January 2024 (or latest available month) by the Respiratory Medicine department with the following drugs:

A2. Please see Table 1 for the number of patients treated by the Respiratory Medicine Department with the listed drugs for the month of October 2023*.

Table 1

Drug Type	Number of Patients Treated
Benralizumab (Fasenra)	Nil
Dupilumab (Dupixent)	Nil
Mepolizumab (Nucala)	Nil
Omalizumab (Xolair)	Nil
Reslizumab (Cinqaero)	Nil
Tezepelumab (Tezspire)	Nil

*Please note, in regards to the figures provided in Tables 1 & 2 the Trust can only provide figures up to 31 October 2023 due to migrating to the new Encompass system.